These results clearly indicated that the cell sensitivity to osimertinib could be increased by the combined treatment with an AXL inhibitor, by predominantly modulating the AKT activity, resulting in reduced viability of high-AXL-expressing EGFR-mutated NSCLC cell lines. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.